share_log

アステラス薬---大幅反落、複数の医薬品の売上予測を下方修正し米系証券が格下げ

Astellas Pharma's stock fell sharply after multiple pharmaceutical sales forecasts were revised downward and U.S. securities downgraded.

Fisco Japan ·  Jul 19 00:58

$Astellas Pharma (4503.JP)$It has declined drastically. At Jeffries Securities, investment decisions have been downgraded from “buy” to “hold,” and the target stock price has also been lowered from 2100 yen to 1700 yen. Sales forecasts for the overactive bladder remedy Mirabegron, hot flashes remedy Veosa, geographic atrophy treatment drug Iservey, etc. have been revised downward, and it seems that the annual sales forecast for the next 5 years will also be reduced by an average of 5%. The EBITDA forecast seems to be about 9% below the consensus.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment